April 03, 2007
New Orphan Biologic Approved
The FDA recently approved a new biologic for the treatment of an extremely rare genetic condition which results in increased blood clotting. Severe Congenital Protein C Deficiency, literally a one-in-a-million condition, manifests symptoms shortly after birth and is fatal if left untreated. The new biologic, Ceprotin, is used in conjunction with other anticoagulant medications to help patients deal with potentially life-threatening situations.
This medication is indicative of the benefits of the Orphan Drug Act, passed in 1983. Without the marketing exclusivity and tax benefits given to firms researching orphan drugs, over 200 drugs would not be on the market. This gives pharmacists and other health care professionals more options to benefit all of their patients.
For more information about Ceprotin, visit http://www.fda.gov/bbs/topics/NEWS/2007/NEW01598.html
Posted by kwiatkg at April 3, 2007 08:28 PM